Date: 2016-05-16
Type of information: Collaboration agreement
Compound:
Company: BiolineRx (Israel) MaRS Innovation (Canada)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On May 16, 2016, BioLineRx announced that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.
Financial terms:
Latest news:
